April 17, 2020:”Twenty-one new studies into the novel coronavirus have been funded by the UK government, including the first clinical drug trial in primary care, vaccine and therapy development, and studying epidemiology, disease transmission, behavioural interventions and policy approaches to COVID-19.
This second round of projects receive £14.1 million as part of the £24.6 million rapid research response funded by UK Research and Innovation (UKRI), and by the Department of Health and Social Care through the National Institute for Health Research (NIHR).
These projects build on the UK’s world-class expertise and capability in global heath and infectious disease that has already shaped our understanding of the pandemic and is informing measures to tackle it. They support the UK government’s efforts to save lives, protect the vulnerable and support the NHS so it can help those who need it the most.
UKRI Chief Executive, Professor Sir Mark Walport said: “The research community’s response to the Covid-19 crisis has been outstanding. In a matter of weeks, researchers have formed projects to develop potential vaccines, repurpose existing drugs and explore the potential for new medicines, and to examine how the virus is transmitted and causes wide variation in symptoms. Pre-clinical trials of vaccines and clinical trials of drugs are already underway.
“The pace at which this work has been carried out is tribute to the UK’s world-class research base and its dedication to the fight against this disease.”
Jonathan Sheffield, NIHR Covid-19 Research Operations Director, said: “In just a few weeks the UK’s health and science communities have risen to the challenges presented by Covid-19 in deeply inspiring ways. Alongside the selfless work being done by our amazing frontline NHS staff, our world-leading research community is also putting its cutting-edge expertise to use in myriad ways.
“Though the studies announced today may vary in theme, they all represent some of the best and brightest scientific research into Covid-19 being done anywhere in the world.”
The projects will run over a maximum 18-month period, ensuring timely insights into the current epidemic.
This research funding has been coordinated with other funders and the World Health Organization to ensure there is not duplication of effort and expertise is applied strategically.
On 30 March, UKRI and NIHR launched a joint rolling call for researchers to apply for funding for short-term projects addressing and mitigating the health, social, economic, cultural and environmental impacts of the COVID-19 outbreak.
Research projects funded:
Professor Christopher Butler, University of Oxford, £1.7 million: The first clinical trial in COVID-19 patients consulting in primary care, ‘PRINCIPLE’, will initially test if the anti-malarial drug hydroxychloroquine can reduce the need for people to go to hospital or speed up their recovery. They will recruit patients aged over 65 years (or aged 50-64 years with underlying health conditions), who consult in primary care (this trial is a national platform trial and is potentially available to all GP practices in the UK) and have COVID-19 symptoms. Patients will be tested for COVID-19 where possible, and will receive either the usual care provided plus hydroxychloroquine 200mg twice a day for 7 days, or, soon, azithromycin for 3-5 days, or usual supportive care without any experimental treatment. The trial aims to recruit over 3,000 people, and has been designed to be flexible, so new suitable treatments can be added into the trial when these become available.
Prof Robin Shattock, Imperial College London, £1.7 million: They have developed a promising RNA vaccine. When it’s injected, it will deliver the genetic instructions to muscle cells to make the SARS-CoV-2 ‘spike’ surface protein, which should provoke an immune response and create immunity to the virus. They have modified the RNA sequence to create a stabilised version of the spike protein, which they hope will provoke the body to produce more protective antibodies. This funding will enable to them to take the vaccine through GMP manufacturing, testing in animal models for safety and efficacy, regulatory and ethical approval, and, if that’s successful, a phase I clinical trial in healthy human volunteers.
Professor Miles Carroll, Public Health England, £0.4 million: They will develop an animal model of SARS-CoV-2 infection in non-human primates, which can be used to test if new vaccines and therapies are effective and, importantly, safe. This will enable researchers to address concerns that vaccines that enhance the immune response could potentially worsen COVID-19.
Dr Stuart Dowall, Public Health England, £0.4 million: Antibodies can bind proteins on the virus surface and disrupt entry into cells. The team aim to create a purified ovine immunoglobulin preparation consisting of polyclonal antibodies (which recognise multiple areas on the target to reduce the chance of escape mutations occurring) by immunising sheep with the SARS-CoV-2 spike protein. The purified ovine immunoglobulin will then be tested for activity to bind and neutralise SARS-CoV-2 virus before testing in animals to determine if it offers protection against infection and disease progression.
Professor Richard Tedder, Imperial College London, £0.4 million: Using the same techniques as previously applied to Zika and Ebola, the team will develop a non-invasive test, using a sample of fluid from the mouth, to detect the immune antibodies (IgG and IgM) that indicate a person has been infected with SARS-CoV-2. They aim to develop a test within 6 months that could be used to diagnose people who have had SARS-CoV-2.
Understanding the prevalence of COVID-19 infections in the community is necessary for NHS planning and the public health response. Information collected by these studies includes: how many people become infected, how many of them become ill, what their symptoms are, how many seek health care, how commonly they transmit to household contacts, what proportion need hospitalisation and what proportion die.
Professor Andrew Hayward,
University College London, £3.2 million: This study ‘Virus Watch’ will
study 25,000 individuals across the country in a nationally representative
household cohort (April to March 2021). Within this cohort, 10,000 people will
be tested for SARS-CoV-2 and other circulating viruses every time they report
symptoms that could be caused by COVID-19. When antibody tests are available,
participants will be invited to have these tests to understand who has been infected
and to measure the protective effect of antibodies. All participants will
provide information on symptoms and behaviour and there will be an optional
mobile app for analysis of movement patterns to help understand how social
distancing measures affect the risk of infection.
Dr Eleni Nastouli, University College London, £1.5 million: 200 healthcare workers at University College London Hospitals NHS Foundation Trust will be tested for SARS-CoV-2 repeatedly over time to assess the risk of acquiring the infection. They will also study healthcare worker behaviour, using digital tracking systems and interviews, and use this data to better inform health and safety measures to protect staff and patients, and hospital infection prevention and control. Ethical questions around staff testing and infection control measures will also be addressed. The team plans to use the data to advise on policy for the current pandemic and preparedness for future ones.
Professor Matthew Snape, Oxford Vaccine Group, University of Oxford, £0.6 million: With Public Health England, they will use an existing study of infectious disease immunity in children and teenagers 0 to 19 years old to study the presence of antibodies against COVID-19 (a marker of having had the disease and now having immunity) in approximately 400 children and teenagers per month for the duration of the COVID-19 outbreak, and they will collect information on recent respiratory illnesses and relevant medical history.
Professor Aziz Sheikh, University of Edinburgh, £0.5 million: Using anonymised electronic health records (including GP and hospital visits and test results) from 1.2 million people in Scotland, they will track the progress of the COVID-19 epidemic in near real-time. They will also process blood samples and swabs of the virus taken from a sub-sample of the participants, to determine who has been exposed and to sequence the virus genomes. If vaccines or anti-viral therapies become available, their effectiveness will be monitored.
Professor Christoph Lees and Dr Ed Mullins, Imperial College London, £0.3 million: To better understand some specific research questions as to how COVID-19 affects early pregnancy, fetal growth, prematurity and virus transmission to the baby the researchers will construct a registry of women with suspected and confirmed COVID-19 from early pregnancy to after delivery of the baby. Healthcare professionals from the UK and across many international centres will contribute data via a web portal.
Behaviour and policy research
Professor Isabel Oliver, Public Health England, £0.4 million: They will evaluate the public health measures, specifically they will conduct surveys and interviews to assess the effectiveness and impacts of the 14 day self-isolation advice on mental health and wellbeing. They will also develop and test different messages to encourage people to follow public health advice, to better inform the current public health response.
Professor Jane Duckett, University of Glasgow, £0.3 million: The research team will study Chinese policy documents and social media databases, and will conduct local interviews in four regions of China. They will document in detail Chinese central and local government measures to tackle the COVID-19 epidemic and evaluate their societal impacts – to inform the international response.
Professor Trudie Lang, University of Oxford, £0.3 million: Building on lessons learnt in the Zika and Ebola outbreaks, the Global Health Network will deliver and share trusted research tools, guidance and training, for example providing guidance on how to run studies in local clinics and hospitals. They will work with partners internationally to create lasting research networks to support evidence generation in challenging settings, so that better quality, standardised data is shared faster worldwide.
Professor Sally Sheard,
University of Liverpool, and Dr Nina Gobat, University of Oxford, £0.3 million:
Working with colleagues at the University of Oxford, they will analyse the UK
pandemic response by collecting real-time responses from senior policymakers
and stakeholders (PHE, DHSC, NHS) and the frontline experiences of healthcare
workers, and by studying media and document sources. Their findings will inform
Professor Lucy Yardley, University of Southampton and University of Bristol, £0.2 million: The ‘Germ-Defence’ website was shown to reduce infection transmission in the home in the swine flu pandemic and seasonal flu years, and will now be rapidly adapted for COVID-19 using novel methods of public engagement and feedback. It will be disseminated in the UK and internationally, evaluating its effects on infection control attitudes and behaviour.
Allan Bennett, Public Health England, £0.3 million: They will study how SARS-CoV-2 can be transmitted, by determining how long SARS-CoV-2 can survive in the air and on different types of surfaces (for example, those found in the healthcare, domestic and community settings) under controlled environmental conditions (a range of temperatures and humidities) representative of those found in different settings and countries. Methods of decontamination will also be investigated.
Dr Sumana Sanyal, University of Oxford, £0.2 million: The virus, SARS-CoV-2, uses enzymes within infected cells called proteases (enzymes which cut up other proteins), so it can replicate and spread. This study will identify which proteases are necessary for the virus, to provide targets for future drugs and vaccine development.
Transmission and mathematical modelling
Dr John Edmunds, London School of Hygiene & Tropical Medicine, £0.5 million: To provide modelling support, including real-time forecasting and scenario analyses, to help improve decisions about the control of COVID-19. In addition, to undertake behavioural surveillance to help track adherence to social distancing measures and how this affects the rate of disease spread within the UK.
Professor Martie van Tongeren, The University of Manchester, £0.3 million: They will investigate the role of gig workers, in particular delivery workers, and delivery supply chains in preventing disease transmission. The project will use interviews with workers and data on deliveries to construct mathematical models to determine how the delivery sector contributes to minimising the risk of spreading the disease and the benefits of additional measures to protect the workers.
Dr Leon Danon, University of Exeter, £0.2 million: The researchers will adapt and develop mathematical models of disease spread and movement within the UK to evaluate the impact of control and mitigation strategies, including travel restrictions, border screening and quarantine policies, and to predict where and when the disease will spread.
Dr Anne Presanis, MRC Biostatistics Unit, University of Cambridge, £0.2 million: To understand the severity of the epidemic – such as the proportion of infections that result in hospitalisation or death – they will use Bayesian statistical models to combine information from multiple datasets emerging from various sources, such as numbers accessing healthcare, numbers of deaths, population surveillance data, and cohort and household studies.
These projects are in addition to six projects funded in the first round which were announced on 23 March.
The NIHR has established a national prioritisation process for COVID-19 research that involves the healthcare system – to prevent duplication of effort and ensure that resources and capacity are not exceeded – and a list of prioritised studies can be found on the NIHR website.”